{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T21:15:15Z","timestamp":1777670115477,"version":"3.51.4"},"reference-count":39,"publisher":"SAGE Publications","issue":"19-20","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Human Gene Therapy"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:p>High interleukin 17A (IL-17A) expression in hepatocellular carcinoma (HCC) tissue promotes HCC development. This study explores a method to inhibit HCC growth by neutralizing IL-17A in the HCC microenvironment. A novel type 5 adenoviral vector (Ad5) that carries DNA sequences encoding specific neutralizing IL-17A recombinant antibody fragments was developed in this research. After locally injecting into tumor tissues, the Ad5 transduced into tumor cells. This leads to the expression of the anti-IL-17A recombinant antibody fragments in the HCC tissue and consequently to an inhibition of HCC growth by neutralizing IL-17A. The stability of the antibody fragments was optimized by different structures design. Stable HCC cell lines that secrete IL-17A continuously were constructed, which showed stronger invasion and migration ability than control HCC cell lines. In addition, the enhanced migration and invasion ability were partially reversed by applying the adenoviral vectors. These results suggest that IL-17A might promote HCC growth by enhancing the invasion and migration ability of hepatoma cells. The antibody fragments from Ad5 neutralized IL-17A locally, in turn inhibiting the growth of HCC tumors. In conclusion, the local administration of Ad5 vectors encoding IL-17A-neutralizing antibody fragments provides a new option for HCC immunotherapy.<\/jats:p>","DOI":"10.1089\/hum.2019.169","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T02:44:14Z","timestamp":1589165054000},"page":"1074-1085","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Gene Therapy for Hepatocellular Carcinoma Using Adenoviral Vectors Delivering a Gene Encoding IL-17A-Neutralizing Antibody Fragments"],"prefix":"10.1177","volume":"31","author":[{"given":"Haoyu","family":"Zou","sequence":"first","affiliation":[{"name":"Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Israth Jahan","family":"Tuhin","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masuma Akter","family":"Monty","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenggen","family":"Luo","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqi","family":"Shao","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Yan","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Yu","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,10,16]]},"reference":[{"key":"e_1_3_5_2_2","first-page":"E359","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"5","author":"Ferlay J","year":"2015","unstructured":"Ferlay J, , Soerjomataram I, , Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015; 5:E359\u2013E386.","journal-title":"Int J Cancer"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.18"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29913"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0044-z"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2015.173"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.12.009"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.4078"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0511-2"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2015.1095092"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00699.x"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.08.041"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.12.033"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20090207"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0904094"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12550"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1221923"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2013.11.041"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-0363"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.3015"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.4.2512-2521.2003"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0711757105"},{"key":"e_1_3_5_23_2","first-page":"4711","article-title":"Delivery approaches of gene therapy in hepatocellular carcinoma","volume":"11","author":"Duan F","year":"2013","unstructured":"Duan F, , Lam MG. Delivery approaches of gene therapy in hepatocellular carcinoma. Anticancer Res, 2013; 11:4711\u20134718.","journal-title":"Anticancer Res"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2014-132923"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng0892-372"},{"key":"e_1_3_5_26_2","doi-asserted-by":"crossref","first-page":"e0163446","DOI":"10.1371\/journal.pone.0163446","article-title":"miRNA-embedded shRNAs for radiation-inducible LGMN knockdown and the antitumor effects on breast cancer","volume":"11","author":"Zhang ZQ","year":"2016","unstructured":"Zhang ZQ, , Cao Z, , Liu C, et al. miRNA-embedded shRNAs for radiation-inducible LGMN knockdown and the antitumor effects on breast cancer. PLoS One, 2016; 11:e0163446.","journal-title":"PLoS One"},{"key":"e_1_3_5_27_2","first-page":"51046","article-title":"In vitro cell migration and invasion assays","volume":"88","author":"Justus CR","year":"2014","unstructured":"Justus CR, , Leffler N, , Ruiz-Echevarria M, et al. In vitro cell migration and invasion assays. J Vis Exp JoVE, 2014; 88:51046.","journal-title":"J Vis Exp JoVE"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxl110"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200809122"},{"key":"e_1_3_5_30_2","doi-asserted-by":"crossref","unstructured":"Borrebaeck CA. Antibody Engineering. Kettering UK: Oxford University Press on Demand 1995.","DOI":"10.1093\/oso\/9780195091502.001.0001"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/9780470595886.ch3"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.377"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2009.06.001"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep03456"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.3727\/096504016X14562725373716"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301343"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.24.13062-13072.2003"},{"key":"e_1_3_5_38_2","first-page":"233","article-title":"Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies","author":"Brennan FR","unstructured":"Brennan FR, , Morton LD, , Spindeldreher S, et al. Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. mAbs, 3:233\u2013255.","journal-title":"mAbs"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2009.08.008"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.10.029"}],"container-title":["Human Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/hum.2019.169","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2019.169","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2019.169","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:55:19Z","timestamp":1777449319000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/hum.2019.169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":39,"journal-issue":{"issue":"19-20","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1089\/hum.2019.169"],"URL":"https:\/\/doi.org\/10.1089\/hum.2019.169","relation":{},"ISSN":["1043-0342","1557-7422"],"issn-type":[{"value":"1043-0342","type":"print"},{"value":"1557-7422","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}